Salivary Gland Cancer

CNS involvement in ACC was associated with poor outcomes despite multimodal therapy. NOTCH1 alterations and leptomeningeal disease were frequent in this cohort, but these findings should be interpreted as hypothesis-generating given the small sample size and absence of a matched non-CNS comparator cohort.

These findings may represent a previously undescribed type of salivary gland tumor. However, additional reports of similar lesions are necessary for definitive characterization.

ETV6-NTRK3 gene translocation is the most reliable basis for diagnosing SC. Combining morphological diagnosis with gene testing is not difficult.

Our study summarizes and updates the clinical features of EMC arising from palatal MSGs. CRD42024542994.

Given the advanced stage, the patient received a systemic combination of tislelizumab, cyclophosphamide, pegylated liposomal doxorubicin, and nedaplatin, initially combined with local intrapleural therapy. This case highlights a diagnostic pitfall in lung tumors exhibiting squamoid immunophenotypes and underscores the necessity of incorporating myoepithelial markers into the diagnostic workup. Furthermore, it provides a cautiously interpreted clinical observation of immune checkpoint inhibitor-based combination therapy in advanced PACC.

P2, N=798, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: May 2027 --> May 2026

A more definitive diagnosis of NF can be established on cytological material using ancillary studies, particularly in situ hybridization (ISH) analysis for USP6 rearrangement, thereby guiding more appropriate clinical management. This report aims to highlight this important diagnostic pitfall and alert cytopathologists by providing an illustrative example.

This study provides new insights into the clinicopathological and molecular features of WL-MEC, confirming its typical presentation (parotid gland, middle-aged females), low-grade behavior, and favorable prognosis after surgical excision. Detection of MAML2 rearrangement is a valuable diagnostic tool for distinguishing WL-MEC from WT.

RNA-seq identified 588 differentially expressed genes associated with MEOX1 overexpression, with enrichment in pathways including cytokine-cytokine receptor interaction, Toll-like receptor signaling, and G protein-coupled receptor signaling. Together, these findings indicate that enforced MEOX1 expression is associated with reduced malignant phenotypes in SACC models and with transcriptomic alterations in pathways related to immune response, G protein-coupled receptor signaling, and DNA damage response.

P2, N=534, Active, not recruiting, Hoffmann-La Roche | Trial completion date: May 2026 --> Jun 2027 | Trial primary completion date: May 2026 --> Jun 2027

Both patients received postoperative radiotherapy at a total dose of 60 Gy. No evidence of local recurrence or distant metastasis has been observed during the follow-up period of 7 years in case 1 and 3 years in case 2.

ADCT-601 demonstrates robust AXL expression linked to anti-tumor activity in preclinical models of ACC, establishing a proof of concept for targeting AXL in this rare cancer. These findings support clinical translation of AXL-targeting ADC as a novel biomarker-driven therapy for patients with ACC.